GlassScriptPhysician profile
Bernard S Bacay
NPI 1629094032
$11,843.73
in general payments reported to CMS, 2019-2025
47 companies · $1,323 in 2025
The $1,323 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,970 · 2020: $1,809 · 2021: $1,763 · 2022: $1,505 · 2023: $1,423 · 2024: $1,050 · 2025: $1,323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,797.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,796.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,566.92 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,284.91 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $1,123.41 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,075.07 | 2019-2025 | Jardiance, Ofev, Jascayd |
| Glaxosmithkline, LLC. | $754.25 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $748.52 | 2021-2025 | |
| Abbvie INC. | $569.11 | 2019-2025 | Vraylar, Qulipta |
| Lilly USA, LLC | $459.20 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Amgen INC. | $448.81 | 2019-2025 | Repatha, Otezla, Repatha |
| E.R. Squibb & Sons, L.L.C. | $258.38 | 2019-2025 | Eliquis |
| Kowa Pharmaceuticals America, INC. | $257.73 | 2019-2023 | Seglentis, Livalo |
| Sanofi-Aventis U.S. LLC | $223.08 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $218.07 | 2019-2025 | Gardasil 9, Capvaxive, M-M-R II |
| Allergan, INC. | $217.50 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $205.23 | 2019-2025 | Rexulti |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bernard Bacay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.